Lantern Pharma is trading 5.3% down at $0.56 in after-hours trading on November 4; no specific company announcement explaining the decline was identified. - Shares had fallen in each of the previous four sessions, following a 20.89% gain on October 28. - No November 4 explanation was found in company press-release listings or available news coverage. Major indices were mixed, and available evidence does not establish a broader-market cause either.